Simcha Therapeutics
Business Services · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
New Haven, Connecticut, United StatesWebsite
www.simchatherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Simcha Therapeutics
Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied both as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in Phase 1/2 clinical trials, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Simcha is seeking to explore additional modalities for IL-18-based therapeutics and capture the full potential of this potentially transformational cytokine.Explore more
Simcha Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Simcha Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Simcha Therapeutics is spiking on competitors!
Simcha Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Simcha Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Simcha Therapeutics recently announced quarterly report
Product Launch: Get notified when Simcha Therapeutics launches new products
Check if Simcha Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Simcha Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Simcha Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Simcha Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Simcha Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Simcha Therapeutics.
Simcha Therapeutics Tech Stack
A closer look at the technologies used by Simcha Therapeutics
Simcha Therapeutics News & Media
Simcha Therapeutics Announces its Scientific Advisory Board, Comprised of Renowned Experts in Immunology and Oncology
SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn.--(BUSINESS WIRE)--Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced the formation of a scientific advisory board that will support the company’s efforts to realize the potential of IL-18-focused therapeutic approaches. “IL-18 has a significant range of potential therapeutic uses across multiple modalities, and Simcha is eager to identify and evaluate the aSimcha Therapeutics Announces First Patient Dosed in Phase 1/2 Study Evaluating ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid Tumors
NEW HAVEN, Conn. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of ST-067, Simcha’s decoy resistant IL-18 agent, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors. The Phase 1/2 open-label, dose-escalation study is evaluatiSimcha Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid Tumors
NEW HAVEN, Conn. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced a clinical trial collaboration with Merck (known as MSD outside the US and Canada) to evaluate clinical safety and benefits of ST-067, Simcha’s decoy resistant IL-18 agent, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors. In conjunctiSimcha Therapeutics Accelerates Growth with Key Leadership Appointments, Expanded Research and Option Agreement with Yale School of Medicine
NEW HAVEN, Conn. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced the appointment of Sanuj Ravindran, M.D., as chief executive officer and director, and Jake Bauer as an independent member and chair of its board of directors. Simcha has also expanded its sponsored research agreement with Yale School of Medicine related to cytokine biology in the laborato
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Simcha Therapeutics
Sign Up For FreeTo access detailed company insights
Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resista... Read More
